INTRODUCTION {#s1}
============

Official guidelines \[[@R1], [@R2]\] identify hepatic resection and radiofrequency ablation (RFA) as two mainstay curative treatments for very early or early hepatocellular carcinoma (HCC). However, 5-year disease-free survival (DFS) associated with these treatments is only about 37% \[[@R3], [@R4]\]. Guidelines recommend transarterial chemoembolization (TACE) for intermediate or advanced HCC \[[@R1],[@R2]\], but progression-free survival (PFS) is also unsatisfactory \[[@R5], [@R6]\]: even after more aggressive hepatic resection, the 5-year recurrence rate can be as high as 74% \[[@R7], [@R8]\]. These data indicate that even after curative surgery, patients with HCC have poor prognosis, highlighting the need for effective adjuvant therapies that improve patient outcomes.

Many postoperative or adjuvant therapies have been described for improving the prognosis of patients with HCC, including adjuvant adoptive immunotherapy (AIT) \[[@R9], [@R10]\]. Two systematic reviews from 2012 concluded that adjuvant AIT for patients with HCC after curative therapies may reduce recurrence rate but may not improve overall survival (OS) \[[@R11], [@R12]\]. These reviews included only a few small studies \[[@R13]--[@R18]\]. Since then, additional randomized controlled trials (RCTs) \[[@R19], [@R20]\] and cohort studies \[[@R21], [@R22]\] have been published with inconsistent findings. Therefore we wanted to perform an updated meta-analysis of the literature to gain a comprehensive understanding of the available evidence on the safety and efficacy of adjuvant AIT.

RESULTS {#s2}
=======

Description of studies {#s2_1}
----------------------

A total of 538 studies were identified, which decreased to 256 after duplicates were removed. Screening the titles and abstracts led to a final set of 20 studies that were read in full \[[@R13]--[@R22], [@R23]--[@R32]\]. Of these, six studies \[[@R23]--[@R28]\] were excluded because they contained subsets of patients already contained in larger studies \[[@R14], [@R15], [@R21], [@R22]\]. Three studies investigating AIT for patients with advanced HCC were excluded \[[@R29]--[@R31]\], and another study investigating a different type of postoperative immunotherapy was excluded \[[@R32]\]. In the end, 8 RCTs \[[@R13]--[@R20]\] and 2 cohort studies \[[@R21], [@R22]\] involving 1,079 AIT-treated and 1041 untreated patients were included in the meta-analysis (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}).

![Flow chart of study selection](oncotarget-08-18537-g001){#F1}

###### Baseline characteristics of included studies

  Study                  Country   Study design    Surgery method                    Child-Pugh score A/B, n (%)   Cirrhosis, *n* (%)   HBV/HCV, *n* (%)
  ---------------------- --------- --------------- --------------------------------- ----------------------------- -------------------- ------------------
  Dong et al. 2009       China     RCT             Curative resection                102/25                        101                  96/NR
  Huang et al. 2013      China     Retrospective   TACE+RFA                          150/24 (86/14)                66                   135/NR
  Kawata et al. 1995     Japan     RCT             Curative resection + adriamycin   NR                            14                   NR
  Lee, et al. 2015       Korea     RCT             Curative resection, RFA, or PEI   226/0                         146                  192/23
  Pan et al. 2015        China     Retrospective   Curative resection                NR                            NR                   866/NR
  Takayama et al. 2000   Japan     RCT             Curative resection                104/46                        73                   29/99
  Weng et al. 2008       China     RCT             TACE+ RFA                         69/16                         NR                   NR/NR
  Xie et al. 2000        China     RCT             Curative resection + TACE         NR                            NR                   NR
  Xu et al. 2016         China     RCT             Curative resection                200/0                         113                  171/NR
  Zhou et al. 1995       China     RCT             Curative resection                NR                            NR                   NR/NR

Abbreviations: AIT, adoptive immunotherapy; HBV, hepatitis B virus; HCV, hepatitis C virus; NR, not reported; PEI, percutaneous ethanol injection; RCT, randomized controlled trial; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

All studies were on patient populations in Asia. Patients in two studies had undergone a sequence of TACE followed by RFA prior to AIT \[[@R16], [@R21]\]. Patients in all other studies had undergone hepatic resection prior to AIT \[[@R13]--[@R15], [@R17]--[@R20], [@R22]\], with patients in one trial also undergoing postoperative transarterial adriamycin chemotherapy \[[@R14]\], and patients in another also receiving postoperative TACE \[[@R17]\]. One trial \[[@R13]\] contained two AIT-treated arms, one treated with 3 cycles and the other with 6 cycles. Data from the two arms were combined. Of all patients in the trial by Zhou et al. \[[@R18]\], only those who underwent resection alone or resection followed by adjuvant AIT were included in the present meta-analysis; this trial reported recurrence data out to 1 year only \[[@R18]\]. Across all studies in the meta-analysis, follow-up ranged from 18 months \[[@R16]\] to more than 6.5 years \[[@R21]\] (Table [2](#T2){ref-type="table"}).

###### Study-level outcomes for HCC patients receiving adjuvant adoptive immunotherapy after curative therapies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                  Recruitment period   Sample size (T/C)   Drugs and doses                                                                                            Follow-up                            Outcome and *P* value for difference ±AIT   Adverse events    
  ---------------------- -------------------- ------------------- ---------------------------------------------------------------------------------------------------------- ------------------------------------ ------------------------------------------- ----------------- --------------------------------
  **DFS or PFS**         **OS**                                                                                                                                                                                                                                                 

  Dong et al. 2009       2000-2002            84/43               Group I: 3 cycles of CIK (1.0-2.0×1010);\                                                                  \>5 yr                               DFS, *P* = 0.001 or 0.004\*                 OS, *P* = 0.884   No long-term events
                                                                  Group II: 6 cycles of CIK (1.0-2.0×1010)                                                                                                                                                                      

  Huang et al. 2013      1999-2012            85/89               NR                                                                                                         Median, 6.5 yr (range, 0.4-14)       PFS, *P* = 0.001                            OS, *P* = 0.001   No grade 3 or 4 adverse events

  Kawata et al. 1995     1989-1990            12/12               13 mg/m2 adriamycin, IL-2, and 2.5×105 LAK daily for 3 weeks                                               NR                                   DFS, *P* = 0.182                            OS, *P* = 0.936   No treatment-related deaths

  Lee, et al. 2015       2008-2012            114/112             16 cycles of CIK cell agent                                                                                About 3 yr                           DFS, *P* = 0.01                             OS, P = 0.080     No\
                                                                                                                                                                                                                                                                                grade 3 or 4 adverse events

  Pan et al. 2015        2001-2009            511/520             At least 4 cycles CIK cells (1.0-1.5×1010) via intravenous infusion                                        NR                                   PFS, *P* = 0.001                            OS, *P* = 0.014   NR

  Takayama et al. 2000   1992-1995            76/74               5 cycles of lymphocytes\                                                                                   Median, 4.4 yr (range, 0.2-6.7)      DFS, *P* = 0.010                            OS, *P* = 0.090   No\
                                                                  (IL-2 + Anti-CD3) (7.1×1010)                                                                                                                                                                                  grade 3 or 4 adverse events

  Weng et al. 2008       2002-2004            45/40               39 patients received 8 cycles of CIK (1.0-1.5×1010); 6 patients received 10 cycles of CIK (1.0-1.5×1010)   Median, 1.5 yr                       DFS, *P* = 0.012                            100% vs. 100%     No\
                                                                                                                                                                                                                                                                                grade 3 or 4 adverse events

  Xie et al. 2000        1994-1996            21/21               TACE + transarterial injection 1×109 LAK/ IL-2 (1×106 U)                                                   NR                                   DFS, *P* \< 0.05                            OS, *P* \< 0.05   NR

  Xu et al. 2016         2008-2013            100/100             4 cycles CIK cells (1.0-1.5×1010) via intravenous infusion                                                 Median, 3.2 (range, 0.3-6.1) years   DFS, *P* = 0.334                            OS, *P* = 0.141   No\
                                                                                                                                                                                                                                                                                grade 3 or 4 adverse events

  Zhou et al. 1995       1992-1992            31/30               4 cycles of LAK + IL-2                                                                                     NR                                   DFS, *P* \< 0.05                            NR                NR
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: AIT, adoptive immunotherapy; CIK, cytokine-induced killer cells; DFS, disease-free survival; IL-2, interleukin-2; LAK, lymphokine-activated killer cells; NR, not reported; OS, overall survival rate; PFS, progression-free survival; TACE, transarterial chemoembolization

\* Group I or II compared to control group.

The present update substantially expands on the two previous systematic reviews comparing recurrence and mortality in patients receiving adjuvant AIT following curative therapies \[[@R11], [@R12]\]. The present work contains two RCTs \[[@R19], [@R20]\] and two cohort studies \[[@R21], [@R22]\], involving 1631 patients, that were not included in those previous reports.

Quality of the included studies {#s2_2}
-------------------------------

Risks of bias in the studies in this meta-analysis were detailed in Table [3](#T3){ref-type="table"}. The methodological quality was high in two studies \[[@R19], [@R20]\] (accounting for 20% of the total patient population), moderate in two \[[@R13], [@R15]\] (accounting for 13% of total patients) and low in the remaining six \[[@R14], [@R16], [@R17], [@R18], [@R21], [@R22]\] (accounting for 67% of total patients).

###### Assessment of methodological quality (internal validity) of included studies

  ------------------------------------------------------------------------------------------------------------------------
  Study                  Random allocation\           Concealment of\     Blinding of persons who\   Intention-to-treat\
                         (description of procedure)   random allocation   assess treatment effects   analysis
  ---------------------- ---------------------------- ------------------- -------------------------- ---------------------
  Dong et al. 2009       \+                           \-                  \-                         \-

  Huang et al. 2013      \-                           \-                  \-                         \-

  Kawata et al. 1995     \-                           \-                  \-                         \-

  Lee, et al. 2015       \+                           \+                  \-                         \+

  Pan et al. 2015        \-                           \-                  \-                         \-

  Takayama et al. 2000   \+                           \-                  \-                         \+

  Weng et al. 2008       \-                           \-                  \-                         \-

  Xie et al. 2000        \-                           \-                  \-                         \-

  Xu et al. 2016         \+                           \+                  \+                         \+

  Zhou et al. 1995       \-                           \-                  \-                         \-
  ------------------------------------------------------------------------------------------------------------------------

Efficacy {#s2_3}
--------

Safety and efficacy data reported by each of the 10 studies in this meta-analysis \[[@R13]--[@R22]\] were summarized in Table [2](#T2){ref-type="table"}. Eight of the 10 studies reported that adjuvant AIT significantly improved DFS or PFS (all *P* \< 0.05) \[[@R13], [@R15]--[@R19], [@R21], [@R22]\], while one small RCT \[[@R17]\] and two retrospective studies \[[@R21], [@R22]\] reported that adjuvant AIT significantly improved OS (all *P* \< 0.05).

Meta-analysis of all 10 studies \[[@R13]--[@R22]\] suggested that adjuvant AIT was associated with significantly lower recurrence rate than curative therapies alone at 1 year (RR 0.64, 95%CI 0.49-0.82), 2 years (RR 0.70, 95%CI 0.59-0.84), 3 years (RR 0.85, 95%CI 0.79-0.91), and 5 years (RR 0.90, 95%CI 0.85-0.95) (Figure [2](#F2){ref-type="fig"}). Similar results were obtained using a random- or fixed-effects meta-analysis model. After excluding the two retrospective studies \[[@R21], [@R22]\], meta-analysis of the remaining 483 AIT-treated patients and 432 controls confirmed the recurrence benefit of adjuvant AIT at 1 year (RR 0.54, 95%CI 0.42-0.71), 2 years (RR 0.63, 95%CI 0.52-0.76) and 3 years (RR 0.81, 95%CI 0.71-0.93) (all *P* \< 0.05). However, adjuvant AIT did not significantly reduce 5-year recurrence rate in this sensitivity analysis (RR 0.92, 95%CI 0.83-1.02).

![Recurrence rate of meta-analysis comparing the efficacy of adjuvant adoptive immunotherapy (AIT) with curative treatment alone](oncotarget-08-18537-g002){#F2}

Meta-analysis of 8 studies \[[@R13]--[@R15], [@R17], [@R19]--[@R22]\] suggested that adjuvant AIT was associated with significantly lower mortality than curative therapies alone at 1 year (RR 0.64, 95%CI 0.52-0.79), 2 years (RR 0.72, 95%CI 0.63-0.83), 3 years (RR 0.73, 95%CI 0.65-0.81), and 5 years (RR 0.86, 95%CI 0.79-0.94) (all *P* \< 0.05; Figure [3](#F3){ref-type="fig"}). Similar results were obtained using a random- or fixed-effects meta-analysis model. Sensitivity analysis using data from only the 6 RCTs \[[@R13]--[@R15], [@R17], [@R19], [@R20]\] supported a benefit of adjuvant AIT for mortality at 1 year (RR 0.39, 95%CI 0.21-0.72) and 2 years (RR 0.51, 95%CI 0.34-0.76), 3 years (RR 0.71, 95%CI 0.55-0.92), but not at 5 years (RR 0.99, 95%CI 0.83-1.19).

![Mortality of meta-analysis comparing the efficacy of adjuvant adoptive immunotherapy (AIT) with curative treatment alone](oncotarget-08-18537-g003){#F3}

AIT-related adverse events {#s2_4}
--------------------------

None of the 10 studies in the meta-analysis reported hospital deaths or serious adverse events attributed to adjuvant AIT. The most frequent adverse events due to AIT were grade 1 fever (defined as persistent or transient temperature of 37.5-39.3°C) and chills. The study with the highest frequency of persistent fever reported it in 5 of 84 (6.0%) patients \[[@R13]\], and none of the 5 was able to complete AIT per protocol because of this condition. In all patients experiencing fever in the meta-analysis, the condition was easily controlled with symptomatic therapies. Rare adverse events included headache, nausea, myalgia, fatigue, dizziness, itching, and tachycardia. All adverse events were grade 1 or 2 and self-limiting. In no case did adverse events cause patients to delay or stop treatment, except for the 5 patients with persistent fever mentioned above. No cases of infection, hepatic deterioration, pulmonary symptoms or autoimmune disorder were reported in the 10 studies.

Assessment of publication bias {#s2_5}
------------------------------

Funnel plots of the 10 studies in the meta-analysis showed a symmetrical shape, suggesting minimal risk of publication bias (Figures [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}).

![Funnel plots to detect any publication bias about recurrence rate](oncotarget-08-18537-g004){#F4}

![Funnel plots to detect any publication bias about mortality](oncotarget-08-18537-g005){#F5}

DISCUSSION {#s3}
==========

HCC is associated with a high recurrence rate, even after curative treatment; in fact, recurrence is the primary cause of death of all patients with HCC. Even after hepatic resection of HCC, patients with large/multinodular HCC can show 5-year DFS of 26%, while this rate can be as low as 18% in those with macrovascular invasion, based on a systematic review of more than 14,000 patients \[[@R33]\]. For such patients, adjuvant TACE shows promise for reducing recurrence and mortality \[[@R34]\]. For patients with hepatitis B virus-related HCC, postoperative antiviral therapy can be safe and effective treatment \[[@R35], [@R36]\]. However, some HCC patients are unfit for TACE or antiviral therapy after surgery. For these patients, and for those with low immune function, which is associated with HCC recurrence \[[@R37]\], adjuvant AIT may prevent tumor relapse. Adjuvant AIT involves transferring immune effectors into the cancer patient in the hopes of stimulating specific anti-tumor immune responses \[[@R38]\]. Such stimulation may counterbalance the strongly immunosuppressive microenvironment in the liver \[[@R39]\].

The present meta-analysis updates two systematic reviews \[[@R11], [@R12]\] from 2012 examining the safety and efficacy of adjuvant AIT for HCC patients who have received curative therapies. In contrast to those previous reports \[[@R11], [@R12]\], this update provides strong evidence that AIT can significantly reduce the rate of tumor recurrence and mortality. The discrepancy between our findings and those of previous systematic reviews likely reflects the more than two decades spanned by the literature, with the first RCTs on AIT for postoperative HCC published in 1995 \[[@R14], [@R18]\] and the most recent in 2016 \[[@R20]\], combined with rapid scientific and technological advances in AIT \[[@R40], [@R41]\]. In addition, no international guidelines or standards exist regarding route of AIT administration, dosing, or cycles. As a result, clinicians can vary substantially in what immune effector cells they use for AIT and what dosing/cycling protocols they follow. Indeed, in the present meta-analysis, AIT was based on three types of immunological effector cells: anti-CD3--activated peripheral blood lymphocytes, cytokine-induced killer cells, and lymphokine-activated killer cells. AIT was administered via injection into the intrahepatic artery \[[@R17], [@R18]\] or via intravenous infusion \[[@R15], [@R16], [@R19]--[@R22]\]. The number of cycles varied from one \[[@R17]\] to 16 \[[@R19]\]. Such heterogeneity highlights the importance of evidence updates like the present one, and the need for systematic assessment and optimization of AIT protocols, perhaps even tailored to HCC type or treatment history.

Our meta-analysis of RCT data suggests that adjuvant AIT can significantly reduce recurrence and mortality at 1, 2 and 3 years, but not 5 years. This may mean that AIT-mediated immune boosting can eliminate small intrahepatic metastases, but it does not prevent multicentric relapse in remnant liver. This hypothesis is consistent with the findings of one study \[[@R20]\] in our meta-analysis that reported that the ability of adjuvant AIT to prevent tumor recurrence was more obvious in the short term and less so in the long term, and that its ability to prolong time to recurrence was greater in patients with tumors \>5 cm, moderately or poorly differentiated tumors, or preoperative α-fetoprotein levels ≥25 ng/mL. Though our results were supported by previous systematic reviews \[[@R42],[@R43]\], the effects of adjuvant AIT on HCC recurrence in the short and long term should be investigated in greater detail.

Patients in two of the included studies underwent minimally invasive treatments \[[@R16], [@R21]\]. In one of these studies, no patient died during the 1.5-year follow-up \[[@R16]\]. In the other study \[[@R21]\], adjuvant AIT significantly improved PFS and OS. These results raise the possibility that the combination of minimally invasive treatments and postoperative AIT may exert synergistic effects. For example, since RFA is known to stimulate the differentiation of natural killer cells and boost their activity \[[@R44]\], it is possible that combining RFA with AIT may further boost immune function and reduce the rate of tumor recurrence. Future studies should investigate the possibility that for suitable patients, the combination of RFA and AIT may be superior to the combination of resection and AIT.

AIT may be based either on human leukocyte antigen-restricted or unrestricted strategies \[[@R45]\]. Cytokine-induced killer cells and lymphokine activated killer cells are heterogeneous mixture of immune effector cells that feature a mixed T- and natural killer cell-like phenotype in their terminally-differentiated CD3+CD56+ subset. Cytokine-induced killer cells and lymphokine activated killer cells can exhibit histocompatibility complex-unrestricted cytotoxicity against a broad range of tumors \[[@R46]\]. Transferred T-cell-based cytotoxicity is the most probable mechanism for anti-CD3-activated peripheral blood lymphocytes \[[@R15]\]. These natural effectors carry out their antitumoral activities without identify and recognize the presence of specific tumor associated antigens expressed on the cells surface. The easy availability, high proliferation rate and widely major histocompatibility complex-unrestricted antitumor activity of three types of cells contribute to their particularly advantageous profile, making them an attractive approach for AIT. Micrometastatic HCC cells are plausible targets. Use of peripheral blood as the source of effectors is supported by the fact that tumour-specific cytotoxic T-cells can be isolated from the peripheral repertoire. However, the extent to which specific T-cell responses contribute to the best clinical outcome needs further clinical trials.

In the past two decades, the scientific interest is focused on oral multikinase inhibitor drugs. However, adjuvant oral multikinase inhibitors provided negative efficacy for HCC after surgery, RFA, or TACE \[[@R47]--[@R51]\], giving the space to explore new effective adjuvant therapies.

The findings of this meta-analysis that adjuvant AIT significantly reduces recurrence and mortality for postoperative HCC must be interpreted with caution. Surgical method, type of cytokines, number of infusion cycles, and duration of maintenance AIT therapy varied among the included studies, creating substantial heterogeneity for which we could not control using sensitivity analyses. Therefore we displayed the efficacy results for each study individually in Table [2](#T2){ref-type="table"}. In addition, length of follow-up varied across the studies and in some cases was too short to observe long-term efficacy of adjuvant AIT. As a result, meta-analysis of outcomes at 3 and 5 years had to be conducted on subsets of all included studies. Some studies did not clearly report procedures for randomization or allocation concealment, increasing the risk of selection or reporting bias. The fourth problem with this meta-analysis is that there are limitations in the original data, which are beyond our control, but nevertheless compromise the value of the study. We know very little about surveillance/screening methodology, diagnostic criteria for HCC, and stage systems for HCC in this meta-analysis. So, a large variability of post-treatment surveillance programs and diagnostic criteria among studies could be expected. The last relevant issue of this meta-analysis is the potential lack of external validity of the results for different populations and settings. All the included studies were conducted on patient populations in Asia. So, a high rate of hepatitis B virus infected patients with or without cirrhosis could be expected. This population may be different in terms of clinical features and comorbidities from most cases of hepatitis C virus-related or post- non-alcoholic steatohepatitis HCC from US and Europe.

Despite these limitations, our meta-analysis provides an updated picture of the evidence based on adjuvant AIT: AIT may be superior to either hepatic resection alone or the combination of TACE followed by RFA for postoperative HCC patients. The findings of the present meta-analysis should be verified and extended in further large trials with adequate follow-up. These studies should aim to expand the range of relevant endpoints examined, such as quality of life, duration of hospital stay, and cost-effectiveness. These studies should also examine the possible clinical benefits of multi-modal immune therapies.

MATERIALS AND METHODS {#s4}
=====================

Literature search strategy {#s4_1}
--------------------------

The most recent on-line versions of the following research databases were searched in June 2016 without language restrictions: Cochrane Library (<http://onlinelibrary.wiley.com/cochranelibrary/search>), Wiley Online Library, Science Direct, Web of Science, Chinese National Knowledge Infrastructure, Embase, and PubMed. The following search terms were used to identify comparative studies: 'hepatocellular carcinoma' *or* HCC *or* 'hepatic cancer' *or* 'hepatic tumor' *or* 'liver tumor' *or* 'liver cancer', *and* 'hepatic resection' *or* hepatectomy *or* 'liver resection' *or* 'transarterial chemoembolization' *or* 'radiofrequency ablation' *or* 'invasive treatment' *or* 'percutaneous ethanol infection', *and* 'adoptive immunotherapy' *or* 'cytokine induced killer cells' *or* 'lymphokine activated killer cells' *or* 'tumor infiltrating lymphocytes' *or* 'interleukin-2'. To avoid missing relevant studies, no filter was imposed to exclude non-controlled studies or non-RCTs. Relevant references were also searched manually to identify additional studies.

Inclusion criteria {#s4_2}
------------------

We included in the meta-analysis full-length research studies that satisfied the following criteria: (a) the study compared the efficacy of curative therapies with or without adjuvant AIT for patients with HCC; (b) the study had a randomized control or cohort design; (c) all tumors were treated by curative procedures before AIT; (d) patients in the AIT and no-AIT arms received otherwise similar treatments; and (e) the study reported sufficient data for estimating risk ratios (RRs) with 95% confidence intervals (95%CIs). Curative therapies for HCC included hepatic resection, RFA, percutaneous ethanol injection, and liver transplantation; these therapies were considered curative if no residual tumor was observed one month after the initial therapy. TACE was defined as palliative therapy for the purposes of this meta-analysis.

Studies were excluded if they evaluated the efficacy of AIT for patients with liver metastases or with recurrent, advanced, or unresectable HCC. Conference abstracts and other forms of summary publication were also excluded. In the case of multiple studies apparently based on the same population, we included only the study with the largest number of participants.

Study identification and data extraction {#s4_3}
----------------------------------------

Studies identified in literature searches were independently screened by two authors (B.-H.Y, R.-H.L), with discrepancies arbitrated by a third author (J.-H.Z). Two authors (B.-H.Y, R.-H.L) independently extracted the following data from included studies using a predefined template: author details, country, study design, surgery method, liver disease, recruitment period, sample size, follow-up period, interventions (drugs, schedules and numbers of therapy sessions), outcomes (positive and negative findings), and methodological quality. A third author (J.-H.Z) checked the extracted data against the original studies. Survival data were taken directly from tables or the text whenever possible; if such data were presented only in graphs, they were extracted by manual interpolation \[[@R33]\]. *P* values associated with inter-group differences in PFS, DFS, or OS were extracted directly from survival curves, text, or tables wherever possible.

Outcome measures {#s4_4}
----------------

The primary outcomes in this meta-analysis were recurrence rate and mortality. The secondary outcome was treatment-related adverse events, which included treatment-related withdrawals and discontinuations.

Quality assessment {#s4_5}
------------------

This meta-analysis was conducted in accordance with the Quality of Reporting of Meta-analyses (QUOROM) statement \[[@R52]\]. Two authors (B.-H.Y, R.-H.L) independently evaluated all included RCTs based on method of randomization, allocation concealment, blinding of outcome assessors, and use of intention-to-treat analysis. RCTs were considered to be of low quality if they reported none of the items, of moderate quality if they reported on fewer than three items and of high quality if they reported on three or four items \[[@R12], [@R52]\]. Quasi-randomized studies and cohort studies were defined to be of low quality.

Missing data {#s4_6}
------------

Meta-analysis was performed on an intention-to-treat basis. To assess attrition bias, we calculated recurrence and mortality using a 'worst-case' approach in which patients with missing data were counted as treatment failures (recurrence or death). For patients with missing data, we 'carried forward' data from the most recent measurement.

Statistical analysis {#s4_7}
--------------------

Review Manager 5.3 (Cochrane Collaboration) was used to analyze data from included studies. Due to the high likelihood of recurrence and mortality, RRs with corresponding 95%CIs were calculated for dichotomous outcomes using the Mantel-Haenszel method. Point estimates of RR were considered statistically significant when *P* \< 0.05. Meta-analysis was carried out using a random-effects model if substantial heterogeneity according to an I-squared threshold was found among included studies; otherwise, the analysis was carried out using a fixed-effect model \[[@R53]\]. If the two models gave different results, we reported both results. Heterogeneity was assessed by calculating I^2^. Homogeneity between studies was analyzed using the χ^2^ test, with significance set at *P* \> 0.1. Publication bias was assessed by visual inspection of Begg\'s funnel plots. Sensitivity analyses excluding cohort studies and choice of random- or fixed-effect meta-analysis model were performed.
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